Moreover, overlapping WA-responsive hypermethyated CpGs with DNA methylation signatures of HER2/PR/ESR positive luminal BC and HER2/PR/ESR negative TNBC patients revealed more pronounced clustering of WA hypermethylated CpGs to epigenetic methylated targets in luminal BC with an improved therapeutic sensitivity (Figure 7B). Here, ERBB2 is linked to breast cancer.